HUTCHMED Executives Receive Over $10M in Vested Equity Awards
HCM sits 26% above its 52-week low of $11.505 on light trading volume (0.2× avg).
Summary
HUTCHMED announced the vesting of over 726,000 ordinary shares, valued at approximately $10.5 million, to its Chief Executive Officer and Chief Financial Officer under its Long Term Incentive Plan.
Key Events · Executive and Board Changes · HCM
-
Executive Equity Vesting
Dr. Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer) and Mr. Johnny Cheng (Executive Director, Acting Chief Executive Officer and Chief Financial Officer) had 524,079 and 202,238 ordinary shares, respectively, vest on March 10, 2026.
-
Significant Compensation Event
The total value of the 726,317 vested shares for both executives is approximately $10.5 million, representing a notable compensation event.
-
Long Term Incentive Plan Awards
These awards were granted on June 5, 2023, under the company's Long Term Incentive Plan, reflecting performance-based compensation.
Analysis · HCM · Life Sciences
This filing details a significant compensation event for HUTCHMED's top executives, with over $10 million in equity awards vesting. While such vesting is a routine part of long-term incentive plans and executive compensation, the substantial value and the involvement of both the CEO and CFO make it a notable event for investors. It represents a form of dilution as new shares are issued, but also serves as a retention mechanism for key leadership. Investors should monitor future compensation disclosures and and the impact of such awards on the company's share count.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCM was trading at $14.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $11.51 to $19.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.